BUY CLENBUTEROL (MONORES) (40 MCG/TAB. – 50 TABS)
-
Product Specifications
- Product: Clenbuterol HCL
- Strength: 40 mcg per tablet
- Active Ingredient: Clenbuterol
- Molecular Formula: C₁₂H₁₈Cl₂N₂O
- Molecular Weight: 313.65 g/mol
- CAS Number: 21898-19-1
- Dosage Form: Tablet
- Route: Oral
- Market Status: Prescription
- Company: Hilma Biocare
- Pack Size: 50 uncoated tablets
- Storage: 15–25°C, protected from light
Main Product Description
Clenbuterol HCL 40 mcg is an oral tablet formulation containing clenbuterol as its active ingredient. According to the supplied product information, clenbuterol is classified as a beta-2 sympathomimetic rather than a steroid hormone. The product information describes its pharmacological activity, therapeutic background, pharmacokinetic characteristics, precautions, adverse reactions and potential drug interactions.
Clenbuterol has been described as a compound used therapeutically in relation to respiratory conditions such as asthma and chronic obstructive pulmonary disease. The supplied information also discusses its use in connection with weight management and athletic performance; however, these uses should not be interpreted as an approved indication without confirmation from the relevant national medicines authority or the authorised product information for the specific market.
The supplied data reports an active life of approximately 68 hours and a half-life of approximately 36–39 hours. It also states that clenbuterol has oral bioavailability of approximately 89–98%. These pharmacokinetic characteristics are relevant to understanding the persistence of the active substance in the body.
Clenbuterol HCL is chemically associated with clenbuterol hydrochloride. The supplied molecular information identifies clenbuterol HCL with the molecular formula C₁₂H₁₈Cl₂N₂O and a molecular weight of 313.65 g/mol. Each tablet contains 40 mcg of the active ingredient, and the product is supplied as 50 uncoated tablets in one bottle.
The pharmacological information supplied describes clenbuterol as a beta-2 sympathomimetic. Its activity can influence the respiratory system and other physiological processes associated with beta-adrenergic stimulation. Because of this pharmacological activity, clenbuterol can produce effects beyond its intended therapeutic action, particularly when used at inappropriate doses or without medical supervision.
The supplied product information also describes effects relating to metabolism and body composition. However, claims concerning fat loss, muscle growth, strength enhancement or athletic performance should be treated separately from established medical indications. Clenbuterol should not be promoted as a general weight-loss or performance-enhancing medicine without appropriate regulatory evidence.
Safety is an important consideration with clenbuterol. The supplied information identifies several possible adverse reactions, including nausea, heartburn, excessive sweating, chest pain, increased blood pressure, insomnia, dry mouth, vomiting, dizziness, nervousness, tremors and muscle cramps. More serious cardiovascular effects may occur following excessive use or misuse. These risks are particularly relevant because beta-adrenergic stimulation can affect heart rate and cardiovascular function.
Clenbuterol is not appropriate for everyone. The supplied information advises against its use in children, pregnant or breastfeeding women and people who may become pregnant while using it. It also lists several cardiovascular, thyroid and other medical conditions for which clenbuterol is not advised, including tachycardia, tachyarrhythmia, hyperthyroidism, heart disease, high blood pressure, coronary artery disease and certain forms of cardiomyopathy.
Drug interactions are another important consideration. Other medicines can potentially enhance or inhibit clenbuterol’s effects and may consequently influence the likelihood or severity of adverse reactions. Patients should therefore provide their doctor or pharmacist with a complete list of prescription medicines, non-prescription medicines and supplements before treatment.
The supplied information specifically advises consultation with a physician before using clenbuterol. This is particularly important because the product is identified as prescription-only in the supplied product data. Individual treatment decisions should therefore be made by a qualified healthcare professional based on the patient’s medical history, current medicines, indication and relevant monitoring requirements.
Clenbuterol HCL 40 mcg is supplied in a 50-tablet pack and should be stored in a cool, dry environment between 15 and 25°C and protected from light. Proper storage helps maintain the quality of the tablets throughout their stated shelf life.
Overall, Clenbuterol HCL 40 mcg is a prescription oral tablet containing clenbuterol. Its pharmacological profile requires careful consideration of cardiovascular effects, contraindications, adverse reactions and potential interactions. The product should be used only according to appropriate professional medical guidance and the authorised product information applicable to the patient’s country.
Clinical Pharmacology
Clenbuterol HCL is described in the supplied information as a beta-2 sympathomimetic rather than a steroid hormone.
The supplied data reports an approximate active life of 68 hours and a half-life of approximately 36–39 hours. Oral bioavailability is reported at approximately 89–98%.
Its pharmacological activity can produce beta-adrenergic effects, which explains both its respiratory pharmacology and the potential for cardiovascular and neurological adverse effects.
Indications and Uses
The supplied information describes clenbuterol in connection with therapeutic treatment of respiratory conditions, including asthma and chronic obstructive pulmonary disease.
It also describes weight-loss and athletic-performance use. These uses should not be presented as approved indications unless independently verified against the authorised medicine information applicable to the relevant country.
Contraindications & Precautions
The supplied information states that clenbuterol should not be used by:
- Children
- Pregnant women
- Breastfeeding women
- People who may become pregnant while using it
- People with known allergy to clenbuterol or its ingredients
It also identifies conditions requiring avoidance or particular medical consideration, including:
- Hyperthyroidism
- Tachycardia
- Tachyarrhythmia
- Heart disease
- High blood pressure
- Coronary artery disease
- Congestive heart failure
- Myocardial infarction
- Ischaemic heart disease
- Hypertrophic obstructive cardiomyopathy
- Glaucoma
- Urinary retention
- Prostatic hypertrophy
Medical supervision is particularly important because of the potential cardiovascular effects of beta-adrenergic stimulation.
Adverse Reactions
The supplied information reports possible adverse effects including:
- Nausea
- Heartburn
- Excessive sweating
- Chest pain
- Increased blood pressure
- Insomnia
- Dry mouth
- Vomiting
- Dizziness
- Nervousness
- Tremors
- Muscle cramps
Excessive use or misuse may result in more serious cardiovascular effects, including palpitations, tachycardia and myocardial infarction.
Seek urgent medical attention for severe chest pain, significant breathing difficulties, fainting, severe palpitations or other serious symptoms.
Drug Interactions
Other medicines may increase or decrease the effects of clenbuterol and may alter the risk of adverse reactions.
Patients should inform their doctor or pharmacist about all medicines, supplements and other products they are taking before using clenbuterol.
The supplied information also mentions potential effects associated with excipients and alcohol-containing formulations. The exact excipient profile should be checked against the authorised product documentation for the specific product.
Dosage & Administration
Because clenbuterol is identified as a prescription medicine in the supplied product information, dosing should be determined by a qualified healthcare professional according to the approved indication and applicable prescribing information.
The source material contains dosing schedules for weight-loss and athletic-performance purposes. These should not be reproduced as recommended medical dosing, as such use may be outside authorised indications and may expose users to significant cardiovascular risks.
Do not increase the dose, change the treatment schedule or use clenbuterol for weight reduction without professional medical supervision.
Overdosage
Excessive exposure to clenbuterol can cause symptoms such as:
- Tremors
- Headache
- Dizziness
- Gastric irritation
- Nausea
- Vomiting
- Excessive sweating
- Palpitations
- Tachycardia
Serious cardiovascular complications have also been reported following excessive use.
Suspected overdose requires prompt medical assessment.
Presentation
Clenbuterol HCL 40 mcg uncoated tablets:
50 tablets supplied in one bottle.
Storage
Store in a cool, dry place between 15–25°C.
Protect from light.
Keep out of reach of children and follow the storage instructions supplied with the product.
